The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020
Open accessAbstract
Background: New York City (NYC) was the US epicenter of the spring 2020 coronavirus disease 2019 (COVID-19) pandemic. We present the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and correlates of seropositivity immediately after the first wave. Methods: From a serosurvey of adult NYC residents (13 May to 21 July 2020), we calculated the prevalence of SARS-CoV-2 antibodies stratified by participant demographics, symptom history, health status, and employment industry. We used multivariable regression models to assess associations between participant characteristics and seropositivity. Results: The seroprevalence among 45 367 participants was 23.6% (95% confidence interval, 23.2%–24.0%). High seroprevalence (>30%) was observed among black and Hispanic individuals, people from high poverty neighborhoods, and people in healthcare or essential worker industry sectors. COVID-19 symptom history was associated with seropositivity (adjusted relative risk, 2.76; 95% confidence interval, 2.65–2.88). Other risk factors included sex, age, race/ethnicity, residential area, employment sector, working outside the home, contact with a COVID-19 case, obesity, and increasing numbers of household members. Conclusions: Based on a large serosurvey in a single US jurisdiction, we estimate that just under one-quarter of NYC adults were infected in the first few months of the COVID-19 epidemic. Given disparities in infection risk, effective interventions for at-risk groups are needed during ongoing transmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Racial health disparities and covid-19 - caution and context
Chowkwanyun, M., & Reed, A. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2012910 · Cited by 706
Flagged first, then by citations
Research works printed but not linked: 22
- Bryan, 2020, Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho, J Clin Microbiol, 58, e00941-20, 10.1128/JCM.00941-20 · DOI
- Menachemi, 2020, Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020, MMWR Morb Mortal Wkly Rep, 69, 960, 10.15585/mmwr.mm6929e1 · DOI
- Biggs, 2020, Estimated community seroprevalence of SARS-CoV-2 antibodies—two Georgia counties, April 28–May 3, 2020, MMWR Morb Mortal Wkly Rep, 69, 965, 10.15585/mmwr.mm6929e2 · DOI
- Sood, 2020, Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles county, California, on April 10–11, 2020, JAMA, 323, 2425, 10.1001/jama.2020.8279 · DOI
- Sutton, 2020, Notes from the field: seroprevalence estimates of SARS-CoV-2 infection in convenience sample—Oregon, May 11–June 15, 2020, MMWR Morb Mortal Wkly Rep, 69, 1100, 10.15585/mmwr.mm6932a4 · DOI
- Rosenberg, 2020, Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York, Ann Epidemiol, 48, 23, 10.1016/j.annepidem.2020.06.004 · DOI
- Thompson, 2020, COVID-19 outbreak—New York City, February 29–June 1, 2020, MMWR Morb Mortal Wkly Rep, 69, 1725, 10.15585/mmwr.mm6946a2 · DOI
- Rocklov, 2020, High population densities catalyse the spread of COVID-19, J Travel Med, 27, taaa038, 10.1093/jtm/taaa038 · DOI
- Millett, 2020, Assessing differential impacts of COVID-19 on black communities, Ann Epidemiol, 47, 37, 10.1016/j.annepidem.2020.05.003 · DOI · Paper page
- Bailey, 2017, Structural racism and health inequities in the USA: evidence and interventions, Lancet, 389, 1453, 10.1016/S0140-6736(17)30569-X · DOI · Paper page
- Moscola, 2020, Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area, JAMA, 324, 893, 10.1001/jama.2020.14765 · DOI
- Self, 2020, Seroprevalence of SARS-CoV-2 among frontline health care personnel in a multistate hospital network—13 academic medical centers, April–June 2020, MMWR Morb Mortal Wkly Rep, 69, 1221, 10.15585/mmwr.mm6935e2 · DOI
- Dooling, 2021, The Advisory Committee on Immunization Practices’ updated interim recommendation for allocation of COVID-19 vaccine—United States, December 2020, MMWR Morb Mortal Wkly Rep, 69, 1657, 10.15585/mmwr.mm695152e2 · DOI
- Oran, 2020, Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review, Ann Intern Med, 173, 362, 10.7326/M20-3012 · DOI
- Havers, Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020, JAMA Intern Med
- Sami, 2021, Prevalence of SARS-CoV-2 antibodies in first responders and public safety personnel in New York City, May–July 2020, Emerg Infect Dis, 27, 796, 10.3201/eid2703.204340 · DOI
- Parrott, 2021, Prevalence of SARS-CoV-2 antibodies in New York City adults, June–October, 2020: a population-based survey, J Infect Dis, 10.1093/infdis/jiab296 · DOI
- Brandstetter, 2020, Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak, Pediatr Allergy Immunol, 31, 841, 10.1111/pai.13278 · DOI
- Gallais, 2021, Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France, Emerg Infect Dis, 27, 113, 10.3201/eid2701.203611 · DOI
- Xiang, 2020, Antibody detection and dynamic characteristics in patients with COVID-19, Clin Infect Dis, 71, 1930, 10.1093/cid/ciaa461 · DOI
- Zhang, 2020, Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019, J Infect Dis, 222, 183, 10.1093/infdis/jiaa229 · DOI
- Cobey, 2020, Modeling infectious disease dynamics, Science, 368, 713, 10.1126/science.abb5659 · DOI
Cited by
Sorted by citations
Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02219-5 · Cited by 198
Fisher, E., Cárdenas, L., Kieffer, E., & Larson, E. (2021) · Geriatric Nursing · doi:10.1016/j.gerinurse.2021.09.002 · Cited by 39
Vial, P., González, C., Icaza, G., Ramirez-Santana, M., Quezada-Gaete, R., Núñez-Franz, L., Apablaza, M., Vial, C., Rubilar, P., Correa, J., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07045-7 · Cited by 31
Metadata
- Authors
- Pathela, P., Crawley, A., Weiss, D., Maldin, B., Cornell, J., Purdin, J., Schumacher, P. K., Marovich, S., Li, J., Daskalakis, D., NYC Serosurvey Team, Pacione, V., Abril, C., Chong, E., & Koehn, J.
- Affiliations
- New York City Department of Health and Mental Hygiene (US)
- Centers for Disease Control and Prevention (US)
- New York City Mayor’s Office of Operations, New York, New York, USA
- Corresponding author
- Pathela, Preeti
- Daskalakis, Demetre
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-04-09
- Volume
- 224
- Issue
- 2
- Pages
- 196-206
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC8083309
- OpenAlex
- W3140392498
- Cited by
- 52
- References
- 4
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 12 · 2022: 21 · 2021: 12
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Occupational Safety and Health
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, serological survey, New York City, racial and ethnic disparities, poverty neighborhoods, healthcare workers, essential workers, COVID-19 symptoms, household transmission, obesity, risk factors
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Female, Humans, Male, Middle Aged, New York City, Risk Factors, Prevalence, Seroepidemiologic Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
